TY - JOUR
T1 - Hypertension in Patients Treated with In-Center Maintenance Hemodialysis
T2 - Current Evidence and Future Opportunities: A Scientific Statement from the American Heart Association
AU - Bansal, Nisha
AU - Artinian, Nancy T.
AU - Bakris, George
AU - Chang, Tara
AU - Cohen, Jordana
AU - Flythe, Jennifer
AU - Lea, Janice
AU - Vongpatanasin, Wanpen
AU - Chertow, Glenn M.
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Nearly 500 000 individuals are treated with maintenance hemodialysis for kidney failure in the United States, and roughly half will die of cardiovascular causes. Hypertension, an important and modifiable risk factor for cardiovascular disease, is observed in >80% of patients treated with maintenance hemodialysis. The pathophysiology of hypertension in patients treated with maintenance hemodialysis is multifactorial and differs from that seen in other patient populations. Factors that contribute to hypertension in patients treated with hemodialysis include volume overload, arterial stiffness, enhanced activity of the sympathetic nervous and renin-angiotensin-aldosterone systems, endothelial dysfunction, and use of erythropoietin-stimulating agents. This scientific statement reviews the current evidence on defining, diagnosing, and treating hypertension in patients treated with maintenance hemodialysis and highlights opportunities for future investigation, including studies on blood pressure targets and treatment strategies.
AB - Nearly 500 000 individuals are treated with maintenance hemodialysis for kidney failure in the United States, and roughly half will die of cardiovascular causes. Hypertension, an important and modifiable risk factor for cardiovascular disease, is observed in >80% of patients treated with maintenance hemodialysis. The pathophysiology of hypertension in patients treated with maintenance hemodialysis is multifactorial and differs from that seen in other patient populations. Factors that contribute to hypertension in patients treated with hemodialysis include volume overload, arterial stiffness, enhanced activity of the sympathetic nervous and renin-angiotensin-aldosterone systems, endothelial dysfunction, and use of erythropoietin-stimulating agents. This scientific statement reviews the current evidence on defining, diagnosing, and treating hypertension in patients treated with maintenance hemodialysis and highlights opportunities for future investigation, including studies on blood pressure targets and treatment strategies.
KW - AHA Scientific Statements
KW - hypertension
KW - kidney
KW - renal dialysis
KW - renin-angiotensin system
UR - http://www.scopus.com/inward/record.url?scp=85159766136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159766136&partnerID=8YFLogxK
U2 - 10.1161/HYP.0000000000000230
DO - 10.1161/HYP.0000000000000230
M3 - Review article
C2 - 37092336
AN - SCOPUS:85159766136
SN - 0194-911X
VL - 80
SP - E112-E122
JO - Hypertension
JF - Hypertension
IS - 6
ER -